Print
04 December 2017
GMP News
Since 2015, the sales of non-opioid analgesics and antipyretics have fallen significantly in physical terms, but are still growing, if calculated based on prices of final consumption, according to retail audit data released by IQVIA.
In the first 9 months of 2017, the market of this group of medicinal products reached 22.3 billion rubles in the prices of final consumption, or 326.1 thousand packages. Moreover, compared to the first 9 months of 2015, the compound annual growth rate (CAGR) for the period was 4% in monetary terms. In physical terms, the demand dropped by 4%.
The analysts attributed this trend to higher average retail price per package which, in the covered period, has risen from 58 to 68 rubles.
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.